BioXcel Therapeutics (BTAI)
(Real Time Quote from BATS)
$1.59 USD
-0.04 (-2.45%)
Updated Jun 5, 2024 02:34 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 21 - 40 ( 109 total )
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Favorable BXCL701 Proof-of-Concept Clinical Data; Raising PT to $79
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRANQUILITY and SERENITY Pivotal Trials Advance; Adjusting PT to $73
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IGALMI Rollout Advances; 2Q22 Financials; Lowering PT to $85
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRANQUILITY II Pivotal Trial Starts; 1Q22 Financials; Lowering PT to $110
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IGALMI Approval on Schedule; Launch Near-Term; Raising PT to $134
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Approval Decision Nears; 2021 Financials; Adjusting PT to $130
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Alzheimer''s Disease Pivotal Program Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Approval Decision Date Delayed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Dementia Pivotal Trial Start Nears; 3Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Clinical Trial Expansion; Pipeline Widens; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Prostate Cancer Clinical Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on BXCL501; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Day Perspectives; Cash Replenished; Lowering PT to $140
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 New Drug Application Accepted for Review; Raising PT to $176
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 NDA Review; Delirium Trial Paused; 1Q21 Financials; PT Lowered to $170
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 RELEASE Trial Yields Mixed Results; Reducing PT to $175
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Gets Breakthrough Therapy Designation in Dementia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focus Shifting to Market Strategy; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Submitted to FDA; Multiple Near-Term Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R